At a glance
ClinicalIndex Comparison RecordN/ACompleted· 46 enrolled
Drug / intervention
capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)
In Brief
An observational study evaluating capecitabine and docetaxel for Breast Cancer. Completed, enrolled 46 participants across 14 sites.
Detailed Summary
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesHungary
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJan 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 29, 2013
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.4 years ago
Interventions
capecitabinedrug
Participants received capecitabine according to individualized physician-prescribed regimen.
docetaxeldrug
Participants received docetaxel according to individualized physician-prescribed regimens.